Gene expression was assessed using microarray technology showing that at least 50 genes are differentially expressed between intestines of LPS-injected and vehicle-injected controls.
More recently, use of microarray technology showed significant differences of gene patterns in skin biopsies from patients with diffuse and limited SSc, which also differed from normal controls.
During the past few years, analysis of animal transcriptomes with the DNA microarray technology showed that many aspects of physiology are directly controlled by the circadian clock through control of the expression of enzymes and regulators involved in these physiological processes [ 5, 6].
Microarray technology has shown promise in predicting outcome in these patients.
In the past few years, protein chip and microarray technology has shown its great potential in the functional analysis of the proteome, clinical diagnostics and drug discovery.
Recent reports, using DNA microarray technology, have shown that the MIC-1 gene is more highly expressed in prostate cancer than in BPH tissues (Buckhaults et al, 2001; Welsh et al, 2001).
Recent advances in microarray technology have shown that subgroups of ALL as well as acute myeloid leukaemia (AML) can be accurately distinguished based on their gene expression profiles [ 10- 16].
Significant expression level changes between these two samples detected only by microarray technology were shown by 4,149 transcripts, resulting in a combined differential tumour epithelial transcriptome of 8,051 genes.
Work from several laboratories exploiting recent DNA microarray technology has shown that H-NS plays a key role in the selective silencing of horizontally acquired genes (Lucchini et al., 2006; Navarre et al., 2006).
It is only through the use of microarray technology, as shown here – which permits simultaneous examination of the relative expression of all known genes – that a comprehensive profile can be developed and the breadth of glucosamine-mediated chondroprotection is fully appreciated.
